Global Search

Hide Filters

Showing 2041 results

Press release / Oct 22, 2018

Novartis COMBI-AD study of Tafinlar® + Mekinist® continues to demonstrate relapse free survival benefit in patients with BRAF V600-mutant stage III melanoma

Extended follow up results confirm leading BRAF/MEK inhibitor combination Tafinlar + Mekinist continues to show relapse free survival benefit Cure rate modeling which estimates fraction of…
Press release / Jan 27, 2015

Novartis erzielt 2014 solide Umsatzsteigerungen, höhere Margen und Fortschritte in der Pipeline; mit der Umgestaltung des Portfolios fokussiert sich das Unternehmen auf führende Geschäftsbereiche

Wachstum des Nettoumsatzes im Jahr 2014 - mit starker Erhöhung der Kerngewinnmarge[1] Der Nettoumsatz steigt 2014 um 1% (+3% kWk[1])[2] auf USD 58,0 Milliarden (4. Quartal: -2%, +4% kWk) Das…
Ad hoc release / Apr 27, 2021

Wichtige Wachstumstreiber und Neueinführungen von Novartis setzen ihre Dynamik im ersten Quartal fort und erhalten das Vertrauen in das Wachstum; Konzernprognose für 2021 bestätigt

Der Nettoumsatz sank im ersten Quartal um –2% (kWk¹, +1% USD) infolge der COVID-19-bedingten Vorratskäufe im Vorjahr (rund USD 0,4 Milliarden) Die Geschäftseinheit Pharmaceuticals blieb…
Press release / Apr 15, 2021

Novartis signs initial agreement to reserve capacity and implement the technology transfer for the production of the active pharmaceutical ingredient for Roche’s Actemra/RoActemra®

Initial agreement covers reservation of the large-scale state-of-the-art biologics facility in Singapore site for the production of the active pharmaceutical ingredient for Roche’s Actemra/RoActemra…
Press release / Mar 13, 2017

Novartis Kisqali® (ribociclib, LEE011) receives FDA approval as first-line treatment for HR+/HER2- metastatic breast cancer in combination with any aromatase inhibitor

Approved based on a first-line Phase III trial that met its primary endpoint of progression-free survival (PFS) at interim analysis due to superior efficacy compared to letrozole alone[1] …
Press release / Nov 30, 2017

Novartis' Cosentyx® is first biologic to show long-term efficacy in nail and palmoplantar psoriasis, which can impact up to 90% of psoriasis patients

Unique Cosentyx® (secukinumab) data reinforce treatment option for up to 90% of psoriasis patients who may develop nail or palmoplantar psoriasis[1]-[4] Cosentyx results represent the first data…
Press release / Oct 10, 2019

Novartis data show Cosentyx® treatment results in rapid and sustained resolution of signs and symptoms of psoriatic arthritis in patients with and without enthesitis

New two-year data compare the effects of Cosentyx (secukinumab) treatment in psoriatic arthritis patients with and without enthesitis, a manifestation described in 30-50% of patients [1] Results…
Press release / May 08, 2019

Novartis data at AAN show Mayzent's® positive impact on cognitive processing speed, a core element of cognitive function, in people living with secondary progressive MS

Data from EXPAND - the largest randomized controlled trial in a representative secondary progressive MS (SPMS) population - show Mayzent® (siponimod) had a meaningful benefit on cognitive…
Press release / Sep 21, 2021

Novartis übernimmt Arctos Medical und erweitert damit ihr Optogenetik-Portfolio, um Patientinnen und Patienten mit einem schwerem Verlust des Sehvermögens Gentherapien anbieten zu können

Mit der Übernahme unterstreicht Novartis ihre Absicht, das Sehvermögen von Patientinnen und Patienten mit einem fortgeschrittenen Sehverlust mittels Optogenetik wiederherzustellenNovartis sichert…
Press release / Oct 26, 2020

Novartis presents promising interim Phase II data of potential first-in-class oral therapy iptacopan (LNP023) in rare renal disease C3 glomerulopathy (C3G)

C3 glomerulopathy (C3G) is a rare renal disease, affecting young patients with a poor prognosis and significant unmet need.1–3 Iptacopan (LNP023) is a potential first-in-class, oral,…

‹ Previous page
1
…
77
78
79
80
81
82
83
…
205
› Next page